Evotec, Halozyme

Evotec plunges amid report it's against Halozyme Therapeutics takeover
ADRs quickly plunged 9% in premarket trading amid a report that the company is preparing to fight back against Halozye Therapeutics (HALO) takeover offer. Shares of Halozyme rose 1%. The German drugmaker has hired Morgan Stanley for a takeover defense,
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery
The stock of German drug-discovery and development company Evotech SE jumped 4% early Monday, after Halozyme Therapeutics Inc. offered an update on its non-binding takeover proposal at 11 euros a share in cash,
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley. Most Read from BloombergSaudi Neom Gets $3 Billion Loan Guarantee From Italy Export Credit Agency SaceThe Urban-Rural Divide Over Highway Expansion and Emissions“We feel confident in being able to fund this as a fully cash deal,
Halozyme provides update on proposal to combine with Evotec
Halozyme Therapeutics (HALO) provided an update on its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash,
Halozyme CEO: Evotec Is Poised for Growth
Halozyme CEO Helen Torley joins to discuss the company's intended acquisition of biotech company Evotech. She speaks with Caroline Hyde on "." (Source: Bloomberg)
Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...
Yahoo Finance2d
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic ...
Halozyme’s Competitive Edge: Butler’s Buy Rating Amid Emerging Competitors
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), with a price target ...
FierceBiotech5d
Halozyme offers $2B for Evotec to expand beyond delivery tech used by J&J and Roche
Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an ...
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer
Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec .
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...
Halozyme宣布计划以20亿欧元收购Evotec
圣地亚哥 - Halozyme Therapeutics, Inc. (NASDAQ: HALO) 今日宣布计划以每股11.00欧元的价格收购Evotec SE (NASDAQ: EVO)，这笔全现金交易总价值20亿欧元。此次交易旨在打造一家全球领先的制药服务公司，显著扩大和多元化Halozyme的业务范围和财务前景。 这项拟议收购预计将利用Halozyme现有技术和Evotec的平台，创建一个收 ...
Halozyme’s Strategic Acquisition of Evotec: A Buy Rating for Future Growth and Profitability
Analyst Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...